<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements</h1>

    <table>
      <tr><th>Ticker</th><td>ASBP</td></tr>
      <tr><th>Float</th><td>3.1 M</td></tr>
      <tr><th>IO</th><td>12.61%</td></tr>
      <tr><th>MC</th><td>7.2 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) announced on February 20, 2026 that Nasdaq has confirmed the company regained compliance with the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The company had previously announced restoration of compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2) on February 10, 2026. Aspire's common stock will remain listed on Nasdaq. Nasdaq also notified Aspire it will remain subject to a Panel Monitor under Listing Rule 5815(d)(4)(B) for one year through February 18, 2027; failure to maintain compliance during that period would require the company to request a hearing before the Panel rather than submit a compliance plan.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Nasdaq confirmed Aspire regained compliance with the $2.5 million minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).</li><li>Company previously regained compliance with the $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)).</li><li>Common stock will remain listed and traded on the Nasdaq Stock Market.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Company will remain subject to a Panel Monitor through February 18, 2027.</li><li>If the company falls out of compliance during the Panel Monitor period, it cannot submit a compliance plan and must request a hearing before the Panel, potentially jeopardizing its listing.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/9ac91dc9-e53b-48ff-9c17-380d54c25a0f" target="_blank">Original Article</a>
    </div>

    <div class="small">ASBP â€¢ TradersLink AI News</div>
  </div>
</body>
</html>